Thread: Igf and Clen?
12-05-2005, 04:08 PM #1Productive Member
- Join Date
- Mar 2005
Igf and Clen?
Would it be wise to run Igf (LR3) and Clen together? I just finished my cycle, and was wanting to run the IGF to keep gaining until my next cycle in April, but also want to run Clen to shed a little fat on the way as well. Any input?
12-05-2005, 04:28 PM #2
im running'em both right now and im lean as hell . . . i give it 2 thumbs up . . . but I’m just a meathead. would be interested for some vets weighing in on this one.
12-06-2005, 11:28 AM #3Productive Member
- Join Date
- Mar 2005
Bump, anyone else?
12-06-2005, 12:23 PM #4
personaly i don't like clen but i see no reason to not run them together. just beware of signs of hypo as they would prob be hard to discover as clen making you shakey.but this is'nt much of an issue with lr3 as with slin.
12-06-2005, 12:45 PM #5Originally Posted by rodge nl.
I certainly do.And feel it's a poor choice to run both concurrently.
12-06-2005, 12:57 PM #6
Am J Physiol Endocrinol Metab. 2002 Jul;283(1):E146-53.Related Articles, Links
Atypical beta-adrenergic effects on insulin sign****g and action in beta(3)-adrenoceptor-deficient brown adipocytes.
Jost P, Fasshauer M, Kahn CR, Benito M, Meyer M, Ott V, Lowell BB, Klein HH, Klein J.
Department of Internal Medicine I, Medical University of Lubeck, 23538 Lubeck, Germany.
Cross talk between adrenergic and insulin sign****g systems may represent a fundamental molecular basis of insulin resistance. We have characterized a newly established beta(3)-adrenoceptor-deficient (beta(3)-KO) brown adipocyte cell line and have used it to selectively investigate the potential role of novel-state and typical beta-adrenoceptors (beta-AR) on insulin sign****g and action. The novel-state beta(1)-AR agonist CGP-12177 strongly induced uncoupling protein-1 in beta(3)-KO brown adipocytes as opposed to the beta(3)-selective agonist CL-316,243. Furthermore, CGP-12177 potently reduced insulin-induced glucose uptake and glycogen synthesis. Neither the selective beta(1)- and beta(2)-antagonists metoprolol and ICI-118,551 nor the nonselective antagonist propranolol blocked these effects. The classical beta(1)-AR agonist dobutamine and the beta(2)-AR agonist clenbuterol also considerably diminished insulin-induced glucose uptake. In contrast to CGP-12177 treatment, these negative effects were completely abrogated by metoprolol and ICI-118,551. Stimulation with CGP-12177 did not impair insulin receptor kinase activity but decreased insulin receptor substrate-1 binding to phosphatidylinositol (PI) 3-kinase and activation of protein kinase B. Thus the present study characterizes a novel cell system to selectively analyze molecular and functional interactions between novel and classical beta-adrenoceptor types with insulin action. Furthermore, it indicates insulin receptor-independent, but PI 3-kinase-dependent, potent negative effects of the novel beta(1)-adrenoceptor state on diverse biological end points of insulin action.
PMID: 12067855 [PubMed - indexed for MEDLINE]
12-06-2005, 03:26 PM #7supersteve Guest
12-07-2005, 09:13 AM #8
Pinn is the man . . . dropped clen yesterday . . .
Would it be ok to keep the T3 and run ECA with IGF??
Im not flat and soft . . . but this is the first time i've run IGF so not totally sure what to expect - i never run clen that high anyway cuz of sides - i've never gone above 40/ed.
12-07-2005, 10:59 AM #9Originally Posted by BobShocker
Users Browsing this Thread
There are currently 1 users browsing this thread. (0 members and 1 guests)